Nektar Therapeutics (NKTR) Misses Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $76.03 +0.70%
EPS Growth %: +28.1%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
MTEX, NSYS, PLNH, More
EPS Growth %: +28.1%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
MTEX, NSYS, PLNH, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $21.69 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
- Southland Holdings (SLND) Misses Q2 EPS by 122c
- Gaxos.ai Inc. (GXAI) Reports Q2 EPS of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
